Multiple Sclerosis

The AJMC® Multiple Sclerosis compendium is a comprehensive resource for clinical news and expert insights for the disabling disease that impacts the brain and spinal cord.

Latest News

brain and protein biomarkers for multiple sclerosis | Image credit: Julien Tromeur - stock.adobe.com
MS Biomarkers Could Lead to a New Era of Personalized Care

September 10th 2025

Discover how biomarkers like neurofilament light chain and glial fibrillary acidic protein enhance personalized care for patients who have multiple sclerosis.

kid with ms and ibd | Image credit: Krakenimages.com - stock.adobe.com
Treatment Challenges, Options for People With MS and Comorbid Inflammatory Diseases

September 8th 2025

Epstein-Barr virus and MS treatments| Image credit: Rasi - stock.adobe.com
Future Therapies Targeting Epstein-Barr Virus Could Help Combat MS

September 5th 2025

brain and multiple sclerosis recovery from relapse | Image credi: vegefox.com - stockadobe.com
Many People With MS Do Not Fully Recover Post Relapse, Meta-Analysis Finds

September 4th 2025

doctor accepting money for prescribing MS medicines | Image credit: Yuliia - stock.adobe.com
Industry Payments Linked to Prescribing Patterns in MS Care

August 28th 2025

Examining the Role of a Novel Class of Medications for the Management of Multiple Sclerosis

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain key insights into managing and understanding this condition.

This video series provides an in-depth look at multiple sclerosis, covering its impact, pathophysiology, treatment strategies, unmet needs, patient satisfaction, and future research. Gain valuable insights into managing and understanding this complex condition.
Continuing Medical Education
View All
September 15th 2025

The Role of the Specialty Pharmacist in Optimizing Treatment for Amyotrophic Lateral Sclerosis: The Impact of Early Intervention, Patient-Centered Care, and Disease-Modifying Therapies in Slowing Disease Progression

1.0 Credit / Neurology
September 15th 2025

Advancing Targeted Therapies Aimed at Smoldering Disease in Multiple Sclerosis

1.0 Credit / Immunology, Neurology
September 15th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology
September 15th 2025

Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

August 21, 2025 | 1:00 PM ET & 8:00 PM ET
September 15th 2025

Overview and Burden of Migraine

0.5 Credit / Neurology
September 15th 2025

The Role of the Pharmacist Migraine Management

0.5 Credit / Neurology
September 15th 2025

The Evolving Treatment Landscape of Migraine

0.5 Credit / Neurology
September 15th 2025

Leveraging Managed Care to Optimize Patient Outcomes: Integrating Novel Treatments in Schizophrenia

1.5 Credits / Neurology, Psychiatry
September 15th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

Misdiagnosis Text, Stethoscope, Syringe, Medication | image credit: Fauzi - stock.adobe.com
December 20th 2023

Diagnostic Delays Drive Misdiagnoses in MS

Kyle Munz
A single-center, observational study conducted in the Czech Republic investigated the determining factors in delayed diagnoses in multiple sclerosis (MS) and how these delays impact patient outcomes.
Clinician Examining MRI of Patient With MS | image credit: New Africa - stock.adobe.com
December 19th 2023

Significant Demographic and Clinical Differences Observed in Patterns Between NMOSD and MS

Isabella Ciccone, MPH
A recent meta-analysis revealed significant differences in characteristic between patients with neuromyelitis optica spectrum disorder (NMOSD) and multiple sclerosis (MS), highlighting the need for enhanced tools to differentiate between these diseases for early and accurate diagnosis.
Top 5 MS Content 2023
December 14th 2023

Top 5 Multiple Sclerosis Content of 2023

Kyle Munz
This year’s most-read articles on multiple sclerosis (MS) explored the emergence of new medications, modes of therapy, and predictive tools in the study of MS.
Multiple Sclerosis Model | image credit: ralwel - stock.adobe.com
December 8th 2023

BTK Inhibitor Evobrutinib Fails to Meet Primary End Points in Phase 3 EVOLUTION Trials

Marco Meglio
Results showed that evobrutinib did not produce a more superior reduction in annualized relapse rates than teriflunomide, a previously approved disease-modifying agent.
Patient Questionnaire Concept | image credit: jannoon028 - stock.adobe.com
November 21st 2023

Patient-Reported Outcomes Reinforce Efficacy of Natalizumab for MS

Kyle Munz
Researchers gathered data on patient-reported outcomes to support evidence for the continuation of natalizumab, a disease-modifying treatment, in the management of multiple sclerosis (MS) progression.
Current stimulation | Image credit: ArtemisDiana - stock.adobe.com
November 17th 2023

Cognitive Benefits in Multiple Sclerosis Seen After Transcranial Current Stimulation

Marco Meglio
Patients with multiple sclerosis (MS) showed cognitive improvements with frontal theta-transcranial alternating current stimulation (tACS), suggesting its potential as a tolerable and beneficial intervention.
Neurons illustration | Image credit: Anna - stock.adobe.com
November 16th 2023

Timing of Neurofilament Light Changes May Predict Multiple Sclerosis Worsening

Marco Meglio
The reported neurofilament light elevation preceding confirmed disability worsening events highlighted the value of NfL as an early biomarker of disability worsening and points to the existence of different windows of dynamic central nervous system pathology.
Dr Erik Wallstroem and Tom Snow Highlight New MS Treatments Aimed at Smoldering Inflammation
November 8th 2023

Dr Erik Wallstroem and Tom Snow Highlight New MS Treatments Aimed at Smoldering Inflammation

Kyle Munz
Three new novel treatments have shown promise in the treatment of multiple sclerosis (MS), including the potential to target neuroinflammation at its source.
Mental Health Model | image credit: Alena - stock.adobe.com
October 24th 2023

Internet-Based CBT Effective for Treating MS-Related Depression, Study Finds

Kyle Munz
A phase 3, randomized, parallel-group trial showcased the efficacy of internet-based cognitive behavioral therapy (iCBT) for combatting depressive symptoms brought on by multiple sclerosis (MS).
Nasal spray | Image credit: PixieMe - stock.adobe.com.jpg
October 23rd 2023

FDA Allows At-Home Dosing of Intranasal Foralumab for Multiple Sclerosis

Isabella Ciccone, MPH
The FDA’s decision to allow at-home dosing of intransal foralumab for patients with multiple sclerosis is likely to improve patient compliance to treatment and health outcomes, according to a recent release statement.
Multiple sclerosis illustration | Image credit: Juan Gärtner - stock.adobe.com
October 12th 2023

Anti-CD20 Therapies Shown to Be Effective After Switch From Natalizumab

Marco Meglio
Following the switch from natalizumab, patients with multiple sclerosis on anti-CD20 therapies like rituximab demonstrated significant reductions in annualized relapse rate.
Myelin Sheath and Neurons | Nathan Devry com - stock.adobe.com
October 11th 2023

Sociodemographic Status Correlates With MS Severity, Study Finds

Kyle Munz
In an observational cohort study, factors such as education, income, and marital status correlated with MS severity outcomes.
Neurodegeneration | Image credit: danang- stock.adobe.com
September 26th 2023

Oral N-Acetylglucosamine Treatment Benefits Management of MS, Study Finds

Kyle Munz
Researchers conducted a cohort study that suggests oral N-acetylglucosamine treatment can hinder neurodegeneration and inflammation associated with multiple sclerosis (MS).
MS | freshidea - stock.adobe.com
September 23rd 2023

Autonomic Dysfunction Significantly Associated With Decreased Quality of Life in MS, NMOSD

Isabella Ciccone, MPH
Findings showed that autonomic symptom burden was slightly more severe in patients with multiple sclerosis (MS) compared with those with NMOSD, although the difference was not statistically significant.
Nerve Damage | ralwel - stock.adobe.com
September 22nd 2023

Researchers Discern Possible Method for More Effective Diagnosis of PPMS

Kyle Munz
In a retrospective, real-world cohort study, the factors complicating the diagnosis of primary progressive forms of multiple sclerosis (PPMS) were explored.
Vaccine image
September 15th 2023

Study Finds No Link Between Vaccines and MS Flare-Ups

Kyle Munz
Researchers add to previous studies by refuting association between vaccines and MS flare-ups.
Patient-Centered Focus Driving
July 17th 2023

Patient-Centered Focus Driving

With their final thoughts, the panelists emphasize patient-centered care is at the forefront of critical MS treatment considerations for providers.
Overall Treatment Objectives for Patients with MS
July 17th 2023

Overall Treatment Objectives for Patients with MS

A comprehensive look into MS treatment objectives is provided.
Site Logo
September 15th 2022

Part I: The Promise of Telehealth – A Cautionary Tale

Neil Minkoff, MD Joshua Greenblatt, BFA Yana Volman, MBA
The rise of telehealth during COVID-19, its limitations, and its uncertain future.
Site Logo
April 8th 2022

ZEPOSIA® (ozanimod), a Sphingosine 1-Phosphate Receptor Modulator for Relapsing Forms of Multiple Sclerosis

teenager playing a video game using a VR headset
January 7th 2022

Active Video Games Improve Balance Better Than Conventional Rehab in MS

Skylar Jeremias
Video games that involve physical exertion was found to be more effective at improving balance in patients with multiple sclerosis (MS) compared with more conventional rehabilitation methods, investigators concluded.
woman walking through forest carrying small weights
January 5th 2022

Review Outlines Effective Diets, Exercise Techniques to Improve MS-Related Outcomes

Skylar Jeremias
A review of published literature revealed which diet methods and forms of physical activity are most effective at improving patient-reported outcomes in patients with multiple sclerosis (MS).
Top 5 Multiple Sclerosis Articles of 2021
December 30th 2021

Top 5 Most-Read Multiple Sclerosis Articles of 2021

Hayden E. Klein
The top 5 most-read multiple sclerosis articles of 2021 focused on artificial intelligence, sunlight exposure, and COVID-19 risk factors, responses, and guidance for people with multiple sclerosis.
young woman administering a vaccine to an older woman
December 23rd 2021

COVID-19 Vaccination May Provide Less Protection for Patients Taking Ocrelizumab, Fingolimod for MS

Skylar Jeremias
After administration of a COVID-19 vaccine, patients with multiple sclerosis (MS) taking ocrelizumab (Ocrevus) or fingolimod (Gilenya) may find themselves less protected against COVID-19 than the general population.
blurry image of a woman face except her eye is in focus
December 22nd 2021

Racial Differences Detected Regarding Impact of Obesity on Retinal Integrity in MS

Skylar Jeremias
Obesity was found to have a significant association with retinal structure abnormalities related to multiple sclerosis (MS); however, the impact may be greater for African Americans than Caucasian Americans.
senior man sitting on couch looking really sad
December 16th 2021

Coping Strategies Can Improve Quality of Life, Physical Disability in People With MS

Skylar Jeremias
Coping strategies can play a role in influencing the health-related quality of life and physical disability of people with multiple sclerosis (MS), researchers concluded.
female doctor holding a vial containing a vaccine
December 14th 2021

Study: 3 Types of COVID-19 Vaccines Deemed Safe for Use in Patients With MS

Skylar Jeremias
Researchers recommend vaccination against COVID-19 for patients with multiple sclerosis (MS) after confirming that several types of vaccines are safe and produced no significant adverse events.
pill being split in 2 to show the inside
December 11th 2021

Smoking, Most DMTs Not Associated With Severe COVID-19 in Patients With MS

Skylar Jeremias
Although obesity, diabetes, and certain comorbidities were all detected as risk factors for severe COVID-19 among people with multiple sclerosis (MS), other long-suspected risk factors, such as smoking and use of most disease-modifying therapies (DMTs), were not.
guy on treadmill
December 10th 2021

Lifestyle Interventions May Be Needed to Improve MS Management, Quality of Life

Skylar Jeremias
Changes to diet, wellness, and physical activity could have a profound effect on patients’ ability to manage their multiple sclerosis (MS) and significantly improve their quality of life at the same time, researchers concluded.
the word "coronavirus" surrounded by images representing different aspects of healthcare
December 1st 2021

Rituximab Infusion Timing, Dosing and COVID-19 Hospitalization Not Linked, Study Says

Skylar Jeremias
A study examining the relation between rituximab infusion and hospitalization as a result of COVID-19 for patients with multiple sclerosis (MS) found that the 2 were not related, contradicting past research.
<12345678
...
22>

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo